Md. Ekramul Haque Ekram
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Md. Ekramul Haque Ekram has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Jahirul Islam Mamun
Department of Pharmacy, Faculty of Biological Sciences, University of Chittagong, Chittagong, Bangladesh
3 shared publications - Hossain Rasel
Department of Pharmacy, Faculty of Biological Sciences University of Chittagong Chittagong Bangladesh
2 shared publications - Mohi Uddin
Department of Pharmacy, Faculty of Biological Sciences University of Chittagong Chittagong Bangladesh
2 shared publications - Tanveer Ahsan
Department of Pharmacy, Faculty of Biological Sciences University of Chittagong Chittagong Bangladesh
2 shared publications - Abdul Alim
Department of Pharmacy, Faculty of Biological Sciences, University of Chittagong, Chittagong, Bangladesh, cu.ac.bd
1 shared publication - Amzad Hasan
Department of Pharmacy University of Science and Technology Chittagong Chattogram Bangladesh
1 shared publication
Latest Publications
- Open Access
- 30 July 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (8) , e72168
Pharmacological Assessment of Calamus guruba Methanolic Extract: Multitarget Effects on Diabetes, Inflammation, Anxiety, and Depression
Calamus guruba Buch.‐Ham. (Family: Arecaceae) is a traditionally valued medicinal plant recognized for its wide range of therapeutic applications. This study was designed to evaluate the antidiabetic, anti‐inflammatory, anxiolytic, and antidepressant properties of the methanolic extract of C. guruba (MECG). Phytochemical screening of the extract was performed according to standard protocols. The antidiabetic potential was assessed using an alpha‐amylase inhibition assay. At the same time, anti‐inflammatory effects were examined using both in vitro (protein denaturation) and in vivo (carrageenan‐ and formalin‐induced paw edema) models. Anxiolytic activity was evaluated using the elevated plus maze (EPM) and hole board test (HBT), and antidepressant effects were determined through the tail suspension test (TST). MECG demonstrated potent antidiabetic activity, with an IC 50 value of 48.69 μg/mL. The extract also showed marked anti‐inflammatory effects in all tested models. MECG showed significant anxiolytic activity ( p < 0.001) in both the EPM and HBT at a dose of 400 mg/kg. Moreover, the same dose significantly decreased immobility time in the TST compared to the control group, indicating robust antidepressant‐like effects. Collectively, these findings suggest that MECG holds promise as a natural therapeutic agent for the management of diabetes, inflammation, anxiety, and depression.
- 30 July 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (8) , e72168
Open AccessPharmacological Assessment of Calamus guruba Methanolic Extract: Multitarget Effects on Diabetes, Inflammation, Anxiety, and Depression
Calamus guruba Buch.‐Ham. (Family: Arecaceae) is a traditionally valued medicinal plant recognized for its wide range of therapeutic applications. This study was designed to evaluate the antidiabetic, anti‐inflammatory, anxiolytic, and antidepressant properties of the methanolic extract of C. guruba (MECG). Phytochemical screening of the extract was performed according to standard protocols. The antidiabetic potential was assessed using an alpha‐amylase inhibition assay. At the same time, anti‐inflammatory effects were examined using both in vitro (protein denaturation) and in vivo (carrageenan‐ and formalin‐induced paw edema) models. Anxiolytic activity was evaluated using the elevated plus maze (EPM) and hole board test (HBT), and antidepressant effects were determined through the tail suspension test (TST). MECG demonstrated potent antidiabetic activity, with an IC 50 value of 48.69 μg/mL. The extract also showed marked anti‐inflammatory effects in all tested models. MECG showed significant anxiolytic activity ( p < 0.001) in both the EPM and HBT at a dose of 400 mg/kg. Moreover, the same dose significantly decreased immobility time in the TST compared to the control group, indicating robust antidepressant‐like effects. Collectively, these findings suggest that MECG holds promise as a natural therapeutic agent for the management of diabetes, inflammation, anxiety, and depression.
- 26 March 2026
- Published by Elsevier in Pharmacological Research - Natural Products
- Vol. 11
Comprehensive evaluation of the methanolic stem extracts of Etlingera linguiformis (Roxb.): Antipyretic, antioxidant, anti-inflammatory, antidiabetic, and thrombolytic activities via In Vitro and In Vivo studies
- 26 March 2026
- Published by Elsevier in Pharmacological Research - Natural Products
- Vol. 11
Comprehensive evaluation of the methanolic stem extracts of Etlingera linguiformis (Roxb.): Antipyretic, antioxidant, anti-inflammatory, antidiabetic, and thrombolytic activities via In Vitro and In Vivo studies
- Open Access
- 1 January 2026
- Published by Wiley in The Scientific World Journal
- Vol. 2026 (1)
Phytochemical Profiling and Neuropharmacological Evaluation of Baccaurea motleyana Bark Extract: In Vivo and In Silico Approaches
Depression, anxiety, insomnia, and muscle spasms are globally prevalent disorders. Although Baccaurea motleyana is traditionally used in folk medicine, its neuroprotective efficacy remains unexplored. This study evaluates the anxiolytic, antidepressant, sedative, and muscle relaxant properties of its bark methanol extract (BMB‐ME) using in vivo and in silico analyses. Phytochemical analysis of BMB‐ME was assessed by gas chromatography–mass spectrometry (GC‐MS). Antidepressant activity was evaluated using the tail suspension test (TST) and forced swim test (FST), anxiolytic effects were assessed using the elevated plus maze (EPM) and hole board test (HBT), sedative effects were measured using the open field test (OFT) and hole cross test (HCT), and muscle relaxant activity was determined using the rotarod test. Moreover, molecular docking and ADMET analyses were performed. GC‐MS of BMB‐ME identified 38 compounds. It significantly reduced immobility in TST to 61.75 ± 1.87 s ( p < 0.001) and in FST to 55.52 ± 3.14 s ( p < 0.001) at 400 mg/kg. EPM results showed increased open arm time to 232.6 ± 7.24 s ( p < 0.001), whereas OFT demonstrated reduced locomotion to 45.6 ± 1.92 ( p < 0.001). Rotarod retention time decreased to 18.6 ± 0.99 s ( p < 0.001), indicating muscle relaxation. Molecular docking showed favorable binding affinities for hexadecanoic acid and gamma‐sitosterol (−8.3 to −8.1 kcal/mol), providing computational support. Overall, BMB‐ME demonstrated preliminary antidepressant‐, anxiolytic‐, sedative‐, and muscle relaxant–like effects in experimental models. Further studies are needed to isolate active compounds and clarify the underlying mechanisms.
- 1 January 2026
- Published by Wiley in The Scientific World Journal
- Vol. 2026 (1)
Open AccessPhytochemical Profiling and Neuropharmacological Evaluation of Baccaurea motleyana Bark Extract: In Vivo and In Silico Approaches
Depression, anxiety, insomnia, and muscle spasms are globally prevalent disorders. Although Baccaurea motleyana is traditionally used in folk medicine, its neuroprotective efficacy remains unexplored. This study evaluates the anxiolytic, antidepressant, sedative, and muscle relaxant properties of its bark methanol extract (BMB‐ME) using in vivo and in silico analyses. Phytochemical analysis of BMB‐ME was assessed by gas chromatography–mass spectrometry (GC‐MS). Antidepressant activity was evaluated using the tail suspension test (TST) and forced swim test (FST), anxiolytic effects were assessed using the elevated plus maze (EPM) and hole board test (HBT), sedative effects were measured using the open field test (OFT) and hole cross test (HCT), and muscle relaxant activity was determined using the rotarod test. Moreover, molecular docking and ADMET analyses were performed. GC‐MS of BMB‐ME identified 38 compounds. It significantly reduced immobility in TST to 61.75 ± 1.87 s ( p < 0.001) and in FST to 55.52 ± 3.14 s ( p < 0.001) at 400 mg/kg. EPM results showed increased open arm time to 232.6 ± 7.24 s ( p < 0.001), whereas OFT demonstrated reduced locomotion to 45.6 ± 1.92 ( p < 0.001). Rotarod retention time decreased to 18.6 ± 0.99 s ( p < 0.001), indicating muscle relaxation. Molecular docking showed favorable binding affinities for hexadecanoic acid and gamma‐sitosterol (−8.3 to −8.1 kcal/mol), providing computational support. Overall, BMB‐ME demonstrated preliminary antidepressant‐, anxiolytic‐, sedative‐, and muscle relaxant–like effects in experimental models. Further studies are needed to isolate active compounds and clarify the underlying mechanisms.